Measure Spotlight – Olanzapine

Olanzapine Prescribed as Part of a 4-Drug Antiemetic Regimen with Cycle 1 High Emetic Risk Chemotherapy

This quality measure focuses on ensuring patients receiving high emetic risk chemotherapy are prescribed a guideline recommended 4 drug antiemetic regimen consisting of:

• NK1 receptor antagonist
• 5HT3 receptor antagonist
• Corticosteroid
• Olanzapine

This combination has been proven to reduce the likelihood of chemotherapy induced nausea and vomiting and improve overall patient experience^1-2. By supporting consistent use of this regimen, the measure aims to prevent unplanned medical visits, reduce treatment related complications, and enhance quality of life during chemotherapy.

Historically, oncology providers have been low prescribers of olanzapine, often due to unfamiliarity with the medication, limited guideline awareness, and the absence of olanzapine in prepopulated order sets³. To improve consistency, practices can embed olanzapine into standard antiemetic order sets and offer provider education to reinforce guideline based use.

For additional guidance on this measure, please refer to MOQC’s Measure Education One Sheet.

Guidelines:

ASCO – https://ascopubs.org/doi/10.1200/JCO.20.01296 

NCCN – https://pubmed.ncbi.nlm.nih.gov/28687576/ 

References:

1. Navari RM et al., 2016, N Engl J Med.
2. Harikul W et al., 2026, Support Care Cancer.
3. Childs DS et al., 2022, JCO Oncol Pract.

New Evidence on Olanzapine Dosing

A recent Lancet Oncology trial found that low dose olanzapine (2.5 mg) works just as well as the standard 10 mg dose for preventing nausea and vomiting from highly emetogenic chemotherapy.

• Much less daytime sleepiness with the 2.5 mg dose — including far fewer severe cases on day 1.
• Study suggests 2.5 mg may be a preferred dosing option when used as part of a 4-drug antiemetic regimen, offering strong control with fewer side effects.

Bajpai J et al. (2024). Low dose vs. standard dose olanzapine for preventing chemotherapy related nausea and vomiting. Lancet Oncology, 25(2), 246–254

MOQC Performance Improvement